Literature DB >> 18770079

Methadone maintenance vs. methadone taper during pregnancy: maternal and neonatal outcomes.

Hendrée E Jones1, Kevin E O'Grady, Debbie Malfi, Michelle Tuten.   

Abstract

This study compared five groups of participants: those receiving either three-day methadone-assisted withdrawal (MAW) alone (n = 67), three-day MAW followed by methadone maintenance (MM) (n = 8), seven-day MAW alone (n = 28), seven-day MAW followed by MM (n = 20), or a continuous MM sample (n = 52) enrolled between 1995-2001 in an urban drug treatment center. On average, patients in the three MM groups remained in treatment longer, attended more obstetrical visits, and more often delivered at the program hospital than patients in the two MAW alone groups. Given the poor maternal MAW outcomes, methadone maintenance should be considered as the primary treatment approach for opioid-dependent pregnant women.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18770079     DOI: 10.1080/10550490802266276

Source DB:  PubMed          Journal:  Am J Addict        ISSN: 1055-0496


  55 in total

1.  Recent trends in treatment admissions for prescription opioid abuse during pregnancy.

Authors:  Caitlin E Martin; Nyaradzo Longinaker; Mishka Terplan
Journal:  J Subst Abuse Treat       Date:  2014-07-23

2.  Nonmedical Use of Prescription Opioids among Pregnant U.S. Women.

Authors:  Katy B Kozhimannil; Amy J Graves; Robert Levy; Stephen W Patrick
Journal:  Womens Health Issues       Date:  2017-04-11

3.  Factors associated with treatment retention in pregnant women with opioid use disorders prescribed methadone or electing non-pharmacological treatment.

Authors:  Brandi Jancaitis; Sydney Kelpin; Saba Masho; James May; Nancy A Haug; Dace Svikis
Journal:  Women Health       Date:  2019-05-08

4.  Clinical care for opioid-using pregnant and postpartum women: the role of obstetric providers.

Authors:  Hendrée E Jones; Krisanna Deppen; Mark L Hudak; Lisa Leffert; Carol McClelland; Leyla Sahin; Jacquelyn Starer; Mishka Terplan; John M Thorp; James Walsh; Andreea A Creanga
Journal:  Am J Obstet Gynecol       Date:  2013-10-10       Impact factor: 8.661

5.  Treatment of Prescription Opioid Use Disorder in Pregnant Women.

Authors:  Constance Guille; Kelly S Barth; Julio Mateus; Jenna L McCauley; Kathleen T Brady
Journal:  Am J Psychiatry       Date:  2017-03-01       Impact factor: 18.112

6.  Medicaid Coverage of Methadone Maintenance and the Use of Opioid Agonist Therapy Among Pregnant Women in Specialty Treatment.

Authors:  Marcus A Bachhuber; Pooja K Mehta; Laura J Faherty; Brendan Saloner
Journal:  Med Care       Date:  2017-12       Impact factor: 2.983

Review 7.  Substance Use in the Perinatal Period.

Authors:  Ariadna Forray; Dawn Foster
Journal:  Curr Psychiatry Rep       Date:  2015-11       Impact factor: 5.285

8.  The relationship between maternal methadone dose at delivery and neonatal outcome: methodological and design considerations.

Authors:  Hendrée E Jones; Lauren M Jansson; Kevin E O'Grady; Karol Kaltenbach
Journal:  Neurotoxicol Teratol       Date:  2013 Sep-Oct       Impact factor: 3.763

9.  Characteristics of opioid-using pregnant women who accept or refuse participation in a clinical trial: screening results from the MOTHER study.

Authors:  Susan M Stine; Sarah H Heil; Karol Kaltenbach; Peter R Martin; Mara G Coyle; Gabriele Fischer; Amelia M Arria; Peter Selby; Hendree E Jones
Journal:  Am J Drug Alcohol Abuse       Date:  2009       Impact factor: 3.829

10.  Induction of pregnant women onto opioid-agonist maintenance medication: an analysis of withdrawal symptoms and study retention.

Authors:  Amber M Holbrook; Hendree E Jones; Sarah H Heil; Peter R Martin; Susan M Stine; Gabriele Fischer; Mara G Coyle; Karol Kaltenbach
Journal:  Drug Alcohol Depend       Date:  2013-03-21       Impact factor: 4.492

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.